Connection

Eric Bartee to Oncolytic Viruses

This is a "connection" page, showing publications Eric Bartee has written about Oncolytic Viruses.
Connection Strength

3.691
  1. TNF blockade enhances the efficacy of myxoma virus-based oncolytic virotherapy. J Immunother Cancer. 2022 05; 10(5).
    View in: PubMed
    Score: 0.806
  2. The use of oncolytic virotherapy in the neoadjuvant setting. J Immunother Cancer. 2022 04; 10(4).
    View in: PubMed
    Score: 0.802
  3. Initial dose of oncolytic myxoma virus programs durable antitumor immunity independent of in vivo viral replication. J Immunother Cancer. 2020 06; 8(1).
    View in: PubMed
    Score: 0.706
  4. Chimeric tumor modeling reveals role of partial PDL1 expression in resistance to virally induced immunotherapy. J Immunother Cancer. 2019 01 16; 7(1):11.
    View in: PubMed
    Score: 0.642
  5. Selective purging of human multiple myeloma cells from autologous stem cell transplantation grafts using oncolytic myxoma virus. Biol Blood Marrow Transplant. 2012 Oct; 18(10):1540-51.
    View in: PubMed
    Score: 0.402
  6. Human cancer cells have specifically lost the ability to induce the synergistic state caused by tumor necrosis factor plus interferon-beta. Cytokine. 2009 Sep; 47(3):199-205.
    View in: PubMed
    Score: 0.333
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.